Brian Chow, Ph.D.

Brian Chow, Ph.D., serves as a principal for Eventide’s private fund, and as a research analyst for other Eventide investments. Dr. Chow has research responsibilities for healthcare investments at Eventide.

Prior to joining Eventide, Dr. Chow was a neuroscience researcher as well as a venture investor. Dr. Chow studied under both Nobel Laureate Dr. Ardem Patapoutian and Dr. Chenghua Gua, a 2021 Howard Hughes Medical Institute Investigator. Dr. Chow’s doctoral research focused on the biological mechanisms underlying the blood-brain barrier, with the potential to enhance drug delivery to the brain to treat neurological disorders. He published his discoveries as first author in the journals Nature and Neuron and wrote several peer-reviewed articles published in Nature Review Neuroscience and Trends in Neuroscience. During Dr. Chow’s doctoral program, he also worked at life sciences venture firm Flagship Pioneering.

Dr. Chow currently serves as an observer on the board of directors of Goldfinch Bio, Biosplice Therapeutics, and Arch Oncology, portfolio companies of certain other Eventide products. Dr. Chow holds a Ph.D. in Neuroscience from Harvard University’s Graduate School of Arts and a BS in Biology and Chemistry from the University of California, San Diego.